MUNICH -- For type 2 diabetes patients uncontrolled on metformin and sitagliptin (Januvia), adding the novel sodium/glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin improved glycemic levels ...

Merck & Co., after settling with nearly two dozen drugmakers aiming to launch generics of its blockbuster Type 2 diabetes med Januvia, has successfully parried a Viatris patent assault in | Merck ...

Merck and Viatris are ready to settle their long-running Januvia patent litigation, they said in recent court filings. But first they need the courts to sign off.